[PDF] HERE - NashBiotechs

Which biotech stocks are looking at Nash?

Of the biotech stocks looking at NASH, Intercept Pharmaceuticals (NASDAQ: ICPT) is already in the lead. That’s because the ICPT is applying one of its other drugs towards the disease. Intercept’s drug Ocaliva is used to treat a rare, chronic liver disease known as primary biliary cholangitis (PBC).

What are the 7 biotechs that failed in Nash?

Those seven are: Intercept Pharmaceuticals, Genfit, NGM Biopharmaceuticals, Akero Therapeutics, Viking Therapeutics, Inventiva Pharma, and 89bio 2019 crumbled into a "graveyard of failures" in NASH, as one Wall Street analyst put it. But the small biotech Intercept stood alone in success.

Which Nash biotechs are set for a quiet 2020?

There are also some significant NASH biotechs set for a quiet 2020, such as Madrigal Pharmaceuticals, which is set to reveal data on how well its treatment works in the second part of next year. This $3 billion biotech solidified its pole position in the race to market in 2019, as potential competition faltered in clinical testing.

Is galectin a good Biotech stock for Nash treatment?

But if GALT is able to get out first and treat a symptom, shares will pop higher. It’s a risky bet on the disease, but for investors looking for a gamble, Galectin could one of the best biotech stocks to own for NASH treatments. As of this writing, Aaron Levitt was long GILD, ICPT, and VXTK stock.